Evidence for anti-osteoporosis therapy in acute fracture situations-Recommendations of a multidisciplinary workshop of the International Society for Fracture Repair

Bone

Volumn 46, Issue 2, 2010, Pages 267-271

  Goldhahn, J ^a   Little, D ^b   Mitchell, P ^c   Fazzalari, N L ^d   Reid, I R ^e   Aspenberg, P ^f   Marsh, D ^g  

^a SCHULTHESS CLINIC   (Switzerland)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c UNIVERSITY OF DERBY   (United Kingdom)

^d HANSON INSTITUTE   (Australia)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

^f LINKÖPING UNIVERSITY   (Sweden)

^g ROYAL NATIONAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

Author keywords

Drug interaction; Drugs; Fracture healing; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; PAMIDRONIC ACID; PARATHYROID HORMONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; ZOLEDRONIC ACID;

BIOMECHANICS; BONE METABOLISM; BONE REMODELING; BONE STRENGTH; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG UTILIZATION; EDITORIAL; EVIDENCE BASED MEDICINE; FRACTURE FIXATION; FRACTURE HEALING; FRAGILITY FRACTURE; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEALTH PERSONNEL ATTITUDE; HUMAN; INHIBITION KINETICS; JAW OSTEONECROSIS; MEDICAL RESEARCH; MEDICAL SOCIETY; NONHUMAN; OSTEOPOROSIS; RELIABILITY; SECONDARY PREVENTION; TREATMENT DURATION; WORKSHOP;

ACUTE DISEASE; EDUCATION; FRACTURE HEALING; FRACTURES, BONE; HEALTH PLANNING GUIDELINES; HUMANS; INTERNATIONAL COOPERATION; OSTEOPOROSIS; SOCIETIES, MEDICAL;

EID: 74249096378     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.10.004     Document Type: Editorial

References (50)

1. Johnell O., and Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17-12 (2006) 1726-1733
2. Johnell O., and Kanis J.A. An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 15-11 (2004) 897-902
3. Dennison E., Mohamed M.A., and Cooper C. Epidemiology of osteoporosis. Rheum Dis Clin North Am 32-4 (2006) 617-629
4. Kanis J.A., Johnell O., De Laet C., Johansson H., Oden A., Delmas P., et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 35-2 (2004) 375-382
5. Klotzbuecher C.M., Ross P.D., Landsman P.B., Abbott III T.A., and Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15-4 (2000) 721-739
6. Giangregorio L., Papaioannou A., Cranney A., Zytaruk N., and Adachi J.D. Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum 35-5 (2006) 293-305
7. Elliot-Gibson V., Bogoch E.R., Jamal S.A., and Beaton D.E. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15-10 (2004) 767-778
8. Seeman E., Compston J., Adachi J., Brandi M.L., Cooper C., Dawson-Hughes B., et al. Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int 18-6 (2007) 711-719
9. King A.B., Saag K.G., Burge R.T., Pisu M., and Goel N. Fracture Reduction Affects Medicare Economics (FRAME): impact of increased osteoporosis diagnosis and treatment. Osteoporos Int 16-12 (2005) 1545-1557
10. Meyer Jr. R.A., Tsahakis P.J., Martin D.F., Banks D.M., Harrow M.E., and Kiebzak G.M. Age and ovariectomy impair both the normalization of mechanical properties and the accretion of mineral by the fracture callus in rats. J Orthop Res 19-3 (2001) 428-435
11. Lill C.A., Hesseln J., Schlegel U., Eckhardt C., Goldhahn J., and Schneider E. Biomechanical evaluation of healing in a non-critical defect in a large animal model of osteoporosis. Journal of Orthopaedic Research 21-5 (2003) 836-842
12. Meyer Jr. R.A., Desai B.R., Heiner D.E., Fiechtl J., Porter S., and Meyer M.H. Young, adult, and old rats have similar changes in mRNA expression of many skeletal genes after fracture despite delayed healing with age. J Orthop Res 24-10 (2006) 1933-1944
13. Xu S.W., Yu R., Zhao G.F., and Wang J.W. Early period of fracture healing in ovariectomized rats. Chin J Traumatol 6-3 (2003) 160-166
14. Namkung-Matthai H., Appleyard R., Jansen J., Hao Lin J., Maastricht S., Swain M., et al. Osteoporosis influences the early period of fracture healing in a rat osteoporotic model. Bone 28-1 (2001) 80-86
15. Melhus G., Solberg L.B., Dimmen S., Madsen J.E., Nordsletten L., and Reinholt F.P. Experimental osteoporosis induced by ovariectomy and vitamin D deficiency does not markedly affect fracture healing in rats. Acta Orthop 78-3 (2007) 393-403
16. Gerstenfeld L.C., Cullinane D.M., Barnes G.L., Graves D.T., and Einhorn T.A. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem 88-5 (2003) 873-884
17. Egermann M., Goldhahn J., and Schneider E. Animal models for fracture treatment in osteoporosis. Osteoporos Int 16 Suppl 2 (2005) S129-S138
18. Auer J.A., Goodship A., Arnoczky S., Pearce S., Price J., Claes L., et al. Refining animal models in fracture research: seeking consensus in optimising both animal welfare and scientific validity for appropriate biomedical use. BMC Musculoskelet Disord 8 (2007) 72
19. O'Loughlin P.F., Morr S., Bogunovic L., Kim A.D., Park B., and Lane J.M. Selection and development of preclinical models in fracture-healing research. J Bone Joint Surg Am 90 Suppl 1 (2008) 79-84
20. McDonald M.M., Dulai S., Godfrey C., Amanat N., Sztynda T., and Little D.G. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone (2008)
21. Cao Y., Mori S., Mashiba T., Westmore M.S., Ma L., Sato M., et al. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 17-12 (2002) 2237-2246
22. Shapiro F. Bone development and its relation to fracture repair. The role of mesenchymal osteoblasts and surface osteoblasts. Eur Cell Mater 15 (2008) 53-76
23. Perren S.M., Linke B., Schwieger K., Wahl D., and Schneider E. Aspects of internal fixation of fractures in porotic bone. Principles, technologies and procedures using locked plate screws. Acta Chir Orthop Traumatol Cech 72-2 (2005) 89-97
24. Andreassen T.T., Ejersted C., and Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 14-6 (1999) 960-968
25. Nakajima A., Shimoji N., Shiomi K., Shimizu S., Moriya H., Einhorn T.A., et al. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res 17-11 (2002) 2038-2047
26. Manabe T., Mori S., Mashiba T., Kaji Y., Iwata K., Komatsubara S., et al. Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone 40-6 (2007) 1475-1482
27. Cebesoy O., Tutar E., Kose K.C., Baltaci Y., and Bagci C. Effect of strontium ranelate on fracture healing in rat tibia. Joint Bone Spine 74-6 (2007) 590-593
28. Goldhahn J, Suhm N, S G, Blauth M, Hanson B. Influence of osteoporosis on fracture fixation-a systematic literature review. Osteoporos Int 2007;19-6:761-72.
29. Aspenberg P. Drugs and fracture repair. Acta Orthop 76-6 (2005) 741-748
30. Moroni A., Faldini C., Hoang-Kim A., Pegreffi F., and Giannini S. Alendronate improves screw fixation in osteoporotic bone. J Bone Joint Surg Am 89-1 (2007) 96-101
31. Hilding M., and Aspenberg P. Local peroperative treatment with a bisphosphonate improves the fixation of total knee prostheses: a randomized, double-blind radiostereometric study of 50 patients. Acta Orthop 78-6 (2007) 795-799
32. Hilding M., and Aspenberg P. Postoperative clodronate decreases prosthetic migration: 4-year follow-up of a randomized radiostereometric study of 50 total knee patients. Acta Orthop 77-6 (2006) 912-916
33. Skripitz R., and Aspenberg P. Implant fixation enhanced by intermittent treatment with parathyroid hormone. J Bone Joint Surg Br 83-3 (2001) 437-440
34. Goldhahn J., Mitlak B., Aspenberg P., Kanis J., Rizzoli R., and Reginster J.-Y. Critical issues in translational and clinical research for the study of new technologies to enhance bone repair. J Bone Joint Surg (Am) 90 Suppl 1 (2008) 43-47
35. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22-10 (2007) 1479-1491
36. Cartsos V.M., Zhu S., and Zavras A.I. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc 139-1 (2008) 23-30
37. Grbic J.T., Landesberg R., Lin S.Q., Mesenbrink P., Reid I.R., Leung P.C., et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 139-1 (2008) 32-40
38. Rizzoli R., Burlet N., Cahall D., Delmas P.D., Eriksen E.F., Felsenberg D., et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42-5 (2008) 841-847
39. Petrella R.J., and Jones T.J. Do patients receive recommended treatment of osteoporosis following hip fracture in primary care?. BMC Fam Pract 7 (2006) 31
40. Majumdar S.R., Johnson J.A., Lier D.A., Russell A.S., Hanley D.A., Blitz S., et al. Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial. Osteoporos Int 18-3 (2007) 261-270
41. Amanat N., McDonald M., Godfrey C., Bilston L., and Little D. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res 22-6 (2007) 867-876
42. O'Donnell S., Cranney A., Wells G.A., Adachi J.D., and Reginster J.Y. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 4 (2006) CD005326
43. Cranney A., Wells G., Willan A., Griffith L., Zytaruk N., Robinson V., et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23-4 (2002) 508-516
44. Wells G.A., Cranney A., Peterson J., Boucher M., Shea B., Robinson V., et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1 (2008) CD001155
45. Ivaska K.K., Gerdhem P., Akesson K., Garnero P., and Obrant K.J. Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res 22-8 (2007) 1155-1164
46. Lenart B.A., Lorich D.G., and Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358-12 (2008) 1304-1306
47. Goh S.K., Yang K.Y., Koh J.S., Wong M.K., Chua S.Y., Chua D.T., et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89-3 (2007) 349-353
48. Schilcher J., and Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop (2009) 1-3
49. Bouxsein M.L., Kaufman J., Tosi L., Cummings S., Lane J., and Johnell O. Recommendations for optimal care of the fragility fracture patient to reduce the risk of future fracture. J Am Acad Orthop Surg 12-6 (2004) 385-395
50. Larsson S. Time to invest in a "fracture liaison nurse"!. Injury 38-11 (2007) 1225-1226